Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus physician's choice chemotherapy versus physician's choice chemotherapy in HER2-positive advanced breast cancer
ChiCTR1900025871Phase 4Not yet recruiting
- Sponsor
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pyrotinib in breast cancer (2 arms), sponsored by Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment. Primary endpoint: progression-free survival. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900025871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025871.